Literature DB >> 7229927

Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon.

P Veng Pedersen.   

Abstract

The pharmacokinetics of cimetidine were evaluated using a linear system analysis that was formulated specifically to resolve the second peak in the blood drug concentration profile after oral dosing. The analysis exemplifies a new approach to pharmacokinetic modeling, which appears to be a valuable alternative to linear compartmental or physiological modeling. The formulation of linear system analysis according to a certain interpretation of a pharmacokinetic phenomenon avoids the complexity of conventional modeling, which often obscures the significance of the kinetic parameters. The new approach should result in a more rational analysis of pharmacokinetic phenomena because the less important pharmacokinetic processes are not specifically modeled but are still accounted for in the mathematical treatment. The bioavailability of cimetidine calculated by deconvolution agrees with previous findings. The model proposed to describe the second peak after oral absorption appears to agree well with the data and the hepatic recycling reported for cimetidine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7229927     DOI: 10.1002/jps.2600700105

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  16 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.

Authors:  A B Suttle; G M Pollack; K L Brouwer
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

3.  Safety and pharmacokinetics of mifentidine after increasing oral doses in healthy subjects.

Authors:  B P Imbimbo; M Seiberling; U Peuckert; G Hoexter; H Maier-Lenz; A Vidi; S Daniotti
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.

Authors:  M D Karol; S Goodrich
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

6.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

7.  Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs.

Authors:  V Mummaneni; G L Amidon; J B Dressman
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

Review 8.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

9.  Linear systems approach to the analysis of an induced drug removal process. Phenobarbital removal by oral activated charcoal.

Authors:  W R Gillespie; P Veng-Pedersen; M J Berg; D D Schottelius
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

Review 10.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.